Archer Materials strengthens human health vertical with biotechnology manager appointed

Archer Materials Ltd (ASX:AXE) (OTCMKTS:ARRXF) has strengthened its human health vertical through the appointment of Dr Rebecca Soffe as biotechnology manager. This newly created role is part of Archer’s strategy to commercially develop materials technology and the immediate priority is to technically develop the intellectual property claims in Archer’s international patent application relevant to the company’s graphene-based biosensor technology. The appointment will build next-stage biosensor prototypes in the $150 million semiconductor chip foundry in Sydney that Archer commercially accesses, lead Archer’s collaboration with University of Adelaide ARC Graphene Hub and work with a leading German biotech company. This comes as Archer progresses the development of biotechnology towards commercialisation. “Talented nanotechnologist” Chief executive officer Dr Mohammad Choucair said: “Dr Soffe is a talented nanotechnologist with an exceptional background in building biosensor devices. “Her track record for high impact innovation related to ‘Lab on a Chip’ technology is world-class and strongly aligns to Archer’s requirements for developing our key vertical of Human Health. “One of the main reasons the company raised funds through the recent share purchase plan was to hire new staff to expedite the development of our deep tech and the prosecution of related patents. “Dr Soffe’s appointment is consistent with this strategy, and we look forward to working with Dr Soffe and expanding our team and capabilities.” International recognition Dr Soffe started the role on September 9 based in Archer’s Sydney CBD office reporting directly to Archer’s CEO. Her experience spans across the design, fabrication and integration of ‘lab on a chip’ biosensor devices. She holds a PhD in Electrical and Computer Engineering from RMIT University, after receiving a Bachelor of Engineering with First Class Honours in Electrical and Electronic Engineering, University of Canterbury (New Zealand). Her innovative work has been recognised internationally and published in peer-reviewed scientific journals which rank in the top percentiles in the field of nanotechnology that continue to be highly cited. Archer's shares have been up as much as 14.6% in early trading to 67 cents.